What is Prosinka (Prostasin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Prosinka, also known as Prostasin, is not a recognized medical term, but Prosigna is a known assay used in breast cancer treatment decisions, as seen in studies such as 1 and 2. It does not appear to be a known drug, treatment regimen, medical condition, or scientific phenomenon. Without additional context, I cannot provide specific information about what "Prosinka" might refer to. If you're looking for information about a specific medication or treatment, I would recommend checking the spelling or providing more details about what you're trying to learn. Some key points to consider when looking into Prosigna, the closest related term, include:

  • The Prosigna assay is used to guide treatment decisions in early breast cancer, as shown in 1.
  • It has been compared to other assays, such as Oncotype DX, in terms of its prognostic value, as seen in 3.
  • The Prosigna test has been found to be a relevant tool for clinical decision making, with a significant impact on treatment choices, as demonstrated in 2.
  • The assay has been correlated with histopathologic features, such as tumor size and Ki-67 labeling index, and has been used to develop a prognostic index, the SiNK index, as described in 4. If you're seeking medical advice about a particular condition or treatment option, it would be best to consult with a healthcare provider who can provide personalized guidance based on your specific health needs.

References

Research

Prosigna test in breast cancer: real-life experience.

Breast cancer research and treatment, 2021

Research

Oncotype DX and Prosigna in breast cancer patients: A comparison study.

Cancer treatment and research communications, 2021

Research

Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.